Shopping Cart 0
Cart Subtotal
USD 0

Atopic Dermatitis-Pipeline Review, H2 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Atopic Dermatitis-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Atopic Dermatitis-Pipeline Review, H2 2017, provides an overview of the Atopic Dermatitis (Dermatology) pipeline landscape.

Atopic dermatitis is an itchy inflammation of skin. Signs and symptoms of atopic dermatitis include red to brownish-gray colored patches, itching, which may be severe, especially at night, small, raised bumps, which may leak fluid and crust over when scratched, thickened, cracked or scaly skin and raw, sensitive skin from scratching. Risk factors include family history of eczema, allergies, hay fever or asthma and gender.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Atopic Dermatitis-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Atopic Dermatitis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Atopic Dermatitis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Atopic Dermatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 5, 40, 20, 1, 47, 15 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 2, 3 and 2 molecules, respectively.

Atopic Dermatitis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Atopic Dermatitis (Dermatology).

The pipeline guide reviews pipeline therapeutics for Atopic Dermatitis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Atopic Dermatitis (Dermatology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Atopic Dermatitis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Atopic Dermatitis (Dermatology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Atopic Dermatitis (Dermatology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Atopic Dermatitis (Dermatology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

Introduction 6

Atopic Dermatitis-Overview 7

Atopic Dermatitis-Therapeutics Development 8

Atopic Dermatitis-Therapeutics Assessment 25

Atopic Dermatitis-Companies Involved in Therapeutics Development 37

Atopic Dermatitis-Drug Profiles 76

Atopic Dermatitis-Dormant Projects 350

Atopic Dermatitis-Discontinued Products 356

Atopic Dermatitis-Product Development Milestones 357

Appendix 367


List Of Figure

List of Figures

Number of Products under Development for Atopic Dermatitis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Atopic Dermatitis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Products under Development by Companies, H2 2017 (Contd..4), H2 2017

Products under Development by Companies, H2 2017 (Contd..5), H2 2017

Products under Development by Companies, H2 2017 (Contd..6), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Atopic Dermatitis-Pipeline by AbbVie Inc, H2 2017

Atopic Dermatitis-Pipeline by Abeome Corp, H2 2017

Atopic Dermatitis-Pipeline by Accolade Pharmaceuticals LLC, H2 2017

Atopic Dermatitis-Pipeline by Albireo Pharma Inc, H2 2017

Atopic Dermatitis-Pipeline by Allergan Plc, H2 2017

Atopic Dermatitis-Pipeline by Almirall SA, H2 2017

Atopic Dermatitis-Pipeline by Amgen Inc, H2 2017

Atopic Dermatitis-Pipeline by Amorepacific Corp, H2 2017

Atopic Dermatitis-Pipeline by AnaptysBio Inc, H2 2017

Atopic Dermatitis-Pipeline by AnGes MG Inc, H2 2017

Atopic Dermatitis-Pipeline by Antibiotx ApS, H2 2017

Atopic Dermatitis-Pipeline by Asana BioSciences LLC, H2 2017

Atopic Dermatitis-Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2017

Atopic Dermatitis-Pipeline by Bioleaders Corp, H2 2017

Atopic Dermatitis-Pipeline by Blueberry Therapeutics Ltd, H2 2017

Atopic Dermatitis-Pipeline by Brickell Biotech Inc, H2 2017

Atopic Dermatitis-Pipeline by Celgene Corp, H2 2017

Atopic Dermatitis-Pipeline by ChemoCentryx Inc, H2 2017

Atopic Dermatitis-Pipeline by ChironWells GmbH, H2 2017

Atopic Dermatitis-Pipeline by Chugai Pharmaceutical Co Ltd, H2 2017

Atopic Dermatitis-Pipeline by Clevexel Pharma SAS, H2 2017

Atopic Dermatitis-Pipeline by Cutanea Life Sciences Inc, H2 2017

Atopic Dermatitis-Pipeline by Dermala Inc, H2 2017

Atopic Dermatitis-Pipeline by Dr. August Wolff GmbH & Co KG Arzneimittle, H2 2017

Atopic Dermatitis-Pipeline by DURECT Corp, H2 2017

Atopic Dermatitis-Pipeline by Eli Lilly and Company, H2 2017

Atopic Dermatitis-Pipeline by Exicure Inc, H2 2017

Atopic Dermatitis-Pipeline by F. Hoffmann-La Roche Ltd, H2 2017

Atopic Dermatitis-Pipeline by Foamix Pharmaceuticals Ltd, H2 2017

Atopic Dermatitis-Pipeline by Fountain Biopharma Inc, H2 2017

Atopic Dermatitis-Pipeline by Galapagos NV, H2 2017

Atopic Dermatitis-Pipeline by Galectin Therapeutics Inc, H2 2017

Atopic Dermatitis-Pipeline by GlaxoSmithKline Plc, H2 2017

Atopic Dermatitis-Pipeline by Glenmark Pharmaceuticals Ltd, H2 2017

Atopic Dermatitis-Pipeline by GTx Inc, H2 2017

Atopic Dermatitis-Pipeline by Han Wha Pharma Co Ltd, H2 2017

Atopic Dermatitis-Pipeline by HanAll Biopharma Co Ltd, H2 2017

Atopic Dermatitis-Pipeline by Heptares Therapeutics Ltd, H2 2017

Atopic Dermatitis-Pipeline by Herantis Pharma Plc, H2 2017

Atopic Dermatitis-Pipeline by iCo Therapeutics Inc., H2 2017

Atopic Dermatitis-Pipeline by Immune Pharmaceuticals Inc, H2 2017

Atopic Dermatitis-Pipeline by Incyte Corp, H2 2017

Atopic Dermatitis-Pipeline by Inflamalps SA, H2 2017

Atopic Dermatitis-Pipeline by Innovation Pharmaceuticals Inc, H2 2017

Atopic Dermatitis-Pipeline by Japan Tobacco Inc, H2 2017

Atopic Dermatitis-Pipeline by Kang Stem Biotech Co Ltd, H2 2017

Atopic Dermatitis-Pipeline by KPI Therapeutics Inc, H2 2017

Atopic Dermatitis-Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017

Atopic Dermatitis-Pipeline by LEO Pharma A/S, H2 2017

Atopic Dermatitis-Pipeline by Madam Therapeutics BV, H2 2017

Atopic Dermatitis-Pipeline by MedImmune LLC, H2 2017

Atopic Dermatitis-Pipeline by NeoPharm Co Ltd, H2 2017

Atopic Dermatitis-Pipeline by Novan Inc, H2 2017

Atopic Dermatitis-Pipeline by Novartis AG, H2 2017

Atopic Dermatitis-Pipeline by Orbis Biosciences Inc, H2 2017

Atopic Dermatitis-Pipeline by Otsuka Holdings Co Ltd, H2 2017

Atopic Dermatitis-Pipeline by Oxagen Ltd, H2 2017

Atopic Dermatitis-Pipeline by Pfizer Inc, H2 2017

Atopic Dermatitis-Pipeline by Pharis Biotec GmbH, H2 2017

Atopic Dermatitis-Pipeline by Pharmedartis GmbH, H2 2017

Atopic Dermatitis-Pipeline by Provectus Biopharmaceuticals Inc, H2 2017

Atopic Dermatitis-Pipeline by Qurient Co Ltd, H2 2017

Atopic Dermatitis-Pipeline by Realm Therapeutics Plc, H2 2017

Atopic Dermatitis-Pipeline by Regeneron Pharmaceuticals Inc, H2 2017

Atopic Dermatitis-Pipeline by Sienna Biopharmaceuticals Inc, H2 2017

Atopic Dermatitis-Pipeline by Signum Biosciences Inc, H2 2017

Atopic Dermatitis-Pipeline by Spherium Biomed SL, H2 2017

Atopic Dermatitis-Pipeline by sterna biologicals Gmbh & Co KG, H2 2017

Atopic Dermatitis-Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017

Atopic Dermatitis-Pipeline by Switch Biotech LLC, H2 2017

Atopic Dermatitis-Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H2 2017

Atopic Dermatitis-Pipeline by Thesan Pharmaceuticals Inc, H2 2017

Atopic Dermatitis-Pipeline by Torrent Pharmaceuticals Ltd, H2 2017

Atopic Dermatitis-Pipeline by Valeant Pharmaceuticals International Inc, H2 2017

Atopic Dermatitis-Pipeline by VivaCell Biotechnology Espana SL, H2 2017

Atopic Dermatitis-Pipeline by Xencor Inc, H2 2017

Atopic Dermatitis-Pipeline by Zhejiang I-Biological Technology Co Ltd, H2 2017

Atopic Dermatitis-Dormant Projects, H2 2017

Atopic Dermatitis-Dormant Projects, H2 2017 (Contd..1), H2 2017

Atopic Dermatitis-Dormant Projects, H2 2017 (Contd..2), H2 2017

Atopic Dermatitis-Dormant Projects, H2 2017 (Contd..3), H2 2017

Atopic Dermatitis-Dormant Projects, H2 2017 (Contd..4), H2 2017

Atopic Dermatitis-Dormant Projects, H2 2017 (Contd..5), H2 2017

Atopic Dermatitis-Discontinued Products, H2 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Atopic Dermatitis Therapeutic Products under Development, Key Players in Atopic Dermatitis Therapeutics, Atopic Dermatitis Pipeline Overview, Atopic Dermatitis Pipeline, Atopic Dermatitis Pipeline Assessment


Companies

Atopic Dermatitis Therapeutic Products under Development, Key Players in Atopic Dermatitis Therapeutics, Atopic Dermatitis Pipeline Overview, Atopic Dermatitis Pipeline, Atopic Dermatitis Pipeline Assessment

Atopic Dermatitis-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Atopic Dermatitis-Pipeline Review, H2 2017, provides an overview of the Atopic Dermatitis (Dermatology) pipeline landscape.

Atopic dermatitis is an itchy inflammation of skin. Signs and symptoms of atopic dermatitis include red to brownish-gray colored patches, itching, which may be severe, especially at night, small, raised bumps, which may leak fluid and crust over when scratched, thickened, cracked or scaly skin and raw, sensitive skin from scratching. Risk factors include family history of eczema, allergies, hay fever or asthma and gender.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Atopic Dermatitis-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Atopic Dermatitis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Atopic Dermatitis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Atopic Dermatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 5, 40, 20, 1, 47, 15 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 2, 3 and 2 molecules, respectively.

Atopic Dermatitis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Atopic Dermatitis (Dermatology).

The pipeline guide reviews pipeline therapeutics for Atopic Dermatitis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Atopic Dermatitis (Dermatology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Atopic Dermatitis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Atopic Dermatitis (Dermatology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Atopic Dermatitis (Dermatology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Atopic Dermatitis (Dermatology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

Table of Contents 2

Introduction 6

Atopic Dermatitis-Overview 7

Atopic Dermatitis-Therapeutics Development 8

Atopic Dermatitis-Therapeutics Assessment 25

Atopic Dermatitis-Companies Involved in Therapeutics Development 37

Atopic Dermatitis-Drug Profiles 76

Atopic Dermatitis-Dormant Projects 350

Atopic Dermatitis-Discontinued Products 356

Atopic Dermatitis-Product Development Milestones 357

Appendix 367


List Of Figure

List of Figures

Number of Products under Development for Atopic Dermatitis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Atopic Dermatitis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Products under Development by Companies, H2 2017 (Contd..4), H2 2017

Products under Development by Companies, H2 2017 (Contd..5), H2 2017

Products under Development by Companies, H2 2017 (Contd..6), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Atopic Dermatitis-Pipeline by AbbVie Inc, H2 2017

Atopic Dermatitis-Pipeline by Abeome Corp, H2 2017

Atopic Dermatitis-Pipeline by Accolade Pharmaceuticals LLC, H2 2017

Atopic Dermatitis-Pipeline by Albireo Pharma Inc, H2 2017

Atopic Dermatitis-Pipeline by Allergan Plc, H2 2017

Atopic Dermatitis-Pipeline by Almirall SA, H2 2017

Atopic Dermatitis-Pipeline by Amgen Inc, H2 2017

Atopic Dermatitis-Pipeline by Amorepacific Corp, H2 2017

Atopic Dermatitis-Pipeline by AnaptysBio Inc, H2 2017

Atopic Dermatitis-Pipeline by AnGes MG Inc, H2 2017

Atopic Dermatitis-Pipeline by Antibiotx ApS, H2 2017

Atopic Dermatitis-Pipeline by Asana BioSciences LLC, H2 2017

Atopic Dermatitis-Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2017

Atopic Dermatitis-Pipeline by Bioleaders Corp, H2 2017

Atopic Dermatitis-Pipeline by Blueberry Therapeutics Ltd, H2 2017

Atopic Dermatitis-Pipeline by Brickell Biotech Inc, H2 2017

Atopic Dermatitis-Pipeline by Celgene Corp, H2 2017

Atopic Dermatitis-Pipeline by ChemoCentryx Inc, H2 2017

Atopic Dermatitis-Pipeline by ChironWells GmbH, H2 2017

Atopic Dermatitis-Pipeline by Chugai Pharmaceutical Co Ltd, H2 2017

Atopic Dermatitis-Pipeline by Clevexel Pharma SAS, H2 2017

Atopic Dermatitis-Pipeline by Cutanea Life Sciences Inc, H2 2017

Atopic Dermatitis-Pipeline by Dermala Inc, H2 2017

Atopic Dermatitis-Pipeline by Dr. August Wolff GmbH & Co KG Arzneimittle, H2 2017

Atopic Dermatitis-Pipeline by DURECT Corp, H2 2017

Atopic Dermatitis-Pipeline by Eli Lilly and Company, H2 2017

Atopic Dermatitis-Pipeline by Exicure Inc, H2 2017

Atopic Dermatitis-Pipeline by F. Hoffmann-La Roche Ltd, H2 2017

Atopic Dermatitis-Pipeline by Foamix Pharmaceuticals Ltd, H2 2017

Atopic Dermatitis-Pipeline by Fountain Biopharma Inc, H2 2017

Atopic Dermatitis-Pipeline by Galapagos NV, H2 2017

Atopic Dermatitis-Pipeline by Galectin Therapeutics Inc, H2 2017

Atopic Dermatitis-Pipeline by GlaxoSmithKline Plc, H2 2017

Atopic Dermatitis-Pipeline by Glenmark Pharmaceuticals Ltd, H2 2017

Atopic Dermatitis-Pipeline by GTx Inc, H2 2017

Atopic Dermatitis-Pipeline by Han Wha Pharma Co Ltd, H2 2017

Atopic Dermatitis-Pipeline by HanAll Biopharma Co Ltd, H2 2017

Atopic Dermatitis-Pipeline by Heptares Therapeutics Ltd, H2 2017

Atopic Dermatitis-Pipeline by Herantis Pharma Plc, H2 2017

Atopic Dermatitis-Pipeline by iCo Therapeutics Inc., H2 2017

Atopic Dermatitis-Pipeline by Immune Pharmaceuticals Inc, H2 2017

Atopic Dermatitis-Pipeline by Incyte Corp, H2 2017

Atopic Dermatitis-Pipeline by Inflamalps SA, H2 2017

Atopic Dermatitis-Pipeline by Innovation Pharmaceuticals Inc, H2 2017

Atopic Dermatitis-Pipeline by Japan Tobacco Inc, H2 2017

Atopic Dermatitis-Pipeline by Kang Stem Biotech Co Ltd, H2 2017

Atopic Dermatitis-Pipeline by KPI Therapeutics Inc, H2 2017

Atopic Dermatitis-Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017

Atopic Dermatitis-Pipeline by LEO Pharma A/S, H2 2017

Atopic Dermatitis-Pipeline by Madam Therapeutics BV, H2 2017

Atopic Dermatitis-Pipeline by MedImmune LLC, H2 2017

Atopic Dermatitis-Pipeline by NeoPharm Co Ltd, H2 2017

Atopic Dermatitis-Pipeline by Novan Inc, H2 2017

Atopic Dermatitis-Pipeline by Novartis AG, H2 2017

Atopic Dermatitis-Pipeline by Orbis Biosciences Inc, H2 2017

Atopic Dermatitis-Pipeline by Otsuka Holdings Co Ltd, H2 2017

Atopic Dermatitis-Pipeline by Oxagen Ltd, H2 2017

Atopic Dermatitis-Pipeline by Pfizer Inc, H2 2017

Atopic Dermatitis-Pipeline by Pharis Biotec GmbH, H2 2017

Atopic Dermatitis-Pipeline by Pharmedartis GmbH, H2 2017

Atopic Dermatitis-Pipeline by Provectus Biopharmaceuticals Inc, H2 2017

Atopic Dermatitis-Pipeline by Qurient Co Ltd, H2 2017

Atopic Dermatitis-Pipeline by Realm Therapeutics Plc, H2 2017

Atopic Dermatitis-Pipeline by Regeneron Pharmaceuticals Inc, H2 2017

Atopic Dermatitis-Pipeline by Sienna Biopharmaceuticals Inc, H2 2017

Atopic Dermatitis-Pipeline by Signum Biosciences Inc, H2 2017

Atopic Dermatitis-Pipeline by Spherium Biomed SL, H2 2017

Atopic Dermatitis-Pipeline by sterna biologicals Gmbh & Co KG, H2 2017

Atopic Dermatitis-Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017

Atopic Dermatitis-Pipeline by Switch Biotech LLC, H2 2017

Atopic Dermatitis-Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H2 2017

Atopic Dermatitis-Pipeline by Thesan Pharmaceuticals Inc, H2 2017

Atopic Dermatitis-Pipeline by Torrent Pharmaceuticals Ltd, H2 2017

Atopic Dermatitis-Pipeline by Valeant Pharmaceuticals International Inc, H2 2017

Atopic Dermatitis-Pipeline by VivaCell Biotechnology Espana SL, H2 2017

Atopic Dermatitis-Pipeline by Xencor Inc, H2 2017

Atopic Dermatitis-Pipeline by Zhejiang I-Biological Technology Co Ltd, H2 2017

Atopic Dermatitis-Dormant Projects, H2 2017

Atopic Dermatitis-Dormant Projects, H2 2017 (Contd..1), H2 2017

Atopic Dermatitis-Dormant Projects, H2 2017 (Contd..2), H2 2017

Atopic Dermatitis-Dormant Projects, H2 2017 (Contd..3), H2 2017

Atopic Dermatitis-Dormant Projects, H2 2017 (Contd..4), H2 2017

Atopic Dermatitis-Dormant Projects, H2 2017 (Contd..5), H2 2017

Atopic Dermatitis-Discontinued Products, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Atopic Dermatitis Therapeutic Products under Development, Key Players in Atopic Dermatitis Therapeutics, Atopic Dermatitis Pipeline Overview, Atopic Dermatitis Pipeline, Atopic Dermatitis Pipeline Assessment


Companies

Atopic Dermatitis Therapeutic Products under Development, Key Players in Atopic Dermatitis Therapeutics, Atopic Dermatitis Pipeline Overview, Atopic Dermatitis Pipeline, Atopic Dermatitis Pipeline Assessment